""
Skip to content

Molecular Genetics Thalassemia lab of The Cyprus Institute of Neurology and Genetics transforms testing with NGS

In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.

  • Instead of running on average three tests per
    patient, they now only run one and get a
    comprehensive analysis
  • The workflow is fast and simple; with just one
    tube we can test most of the thalassemias
    almost 100%
  • They can save on average 4 weeks for a patient
    waiting for their diagnosis

Get access to the case study by filling out the form below

Whitepaper

Advancing kidney transplant outcomes through dual-donor cfDNA monitoring

This whitepaper details how dd-cfDNA monitoring represents a significant advancement in the field of kidney transplantation. Offering a  non-invasive and sensitive method for early detection of graft rejection can potentially improve patient outcomes and transform post-transplant care. 


The study discussed in this whitepaper validates the feasibility of dd-cfDNA monitoring to differentiate between sources of dd-cfDNA (Pettersson et al., 2024). The study even highlighted the challenge faced by dd-cfDNA monitoring, as the assay detected dd-cfDNA from an organ explanted 8 years previously. The NGS-based methodology allows for scalable deployment of the technology, with the ability to analyze multiple samples with a turnaround time acceptable for clinical applications.